Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease
| Autor: | Nicholas V. DiPatrizio, Fjolla Muqolli, Donovan A Argueta, Varun Sagi, Anupam Aich, Kalpna Gupta, Hemanth Cherukury |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
cannabis
congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty Clinical Sciences lcsh:Medicine Review Disease 03 medical and health sciences Rare Diseases 0302 clinical medicine hemic and lymphatic diseases medicine pain 030212 general & internal medicine Health risk Adverse effect Intensive care medicine Sickle Cell Disease Cannabinoid Research biology business.industry vaso-occlusive crises lcsh:R Pain Research Neurosciences Chronic pain Hematology General Medicine cannabinoid Pain management Cannabis use medicine.disease biology.organism_classification Comorbidity Good Health and Well Being sickle cell disease Generic health relevance Cannabis Chronic Pain business 030217 neurology & neurosurgery |
| Zdroj: | Journal of clinical medicine, vol 9, iss 12 Journal of Clinical Medicine, Vol 9, Iss 3902, p 3902 (2020) Journal of Clinical Medicine |
| ISSN: | 2077-0383 |
| Popis: | Pain in Sickle Cell Disease (SCD) is a major comorbidity and unique with acute pain due to recurrent and episodic vaso-occlusive crises as well as chronic pain, which can span an individual’s entire life. Opioids are the mainstay treatment for pain in SCD. Due to recent health crises raised by adverse effects including deaths from opioid use, pain management in SCD is adversely affected. Cannabis and its products are most widely used for pain in multiple conditions and also by patients with SCD on their own. With the availability of “Medical Cannabis” and approval to use cannabis as medicine across majority of States in the United States as well as over-the-counter preparations, cannabis products are being used increasingly for SCD. The reliability of many of these products remains questionable, which poses a major health risk to the vulnerable individuals seeking pain relief. Therefore, this review provides up to date insights into available categories of cannabis-based treatment strategies, their mechanism of action and pre-clinical and clinical outcomes in SCD. It provides evidence for the benefits and risks of cannabis use in SCD and cautions about the unreliable and unvalidated products that may be adulterated with life-threatening non-cannabis compounds. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |